It's been awhile since I've look at this message board.
You're now a convicted 1st degree PUMPER. Confirmed!
IF, as you say, it's a "long-term" development ($3.3M) why would the shorts need to cover so quickly? (As in "tomorrow.")
I have to admit, you DO make me chuckle at times.
I agree with you on that. But I will say this. It's very unlikely. One has to go with the best odds with the best information which is available.
Can you tell me (with information available now) of any specific catalysts in 2015 which will first move the PPS substantially higher than 0.50 and then sustain it there for more than 5 minutes? (Note: ONCS reached a high of 0.97 last year, but that's a bit misleading. It held that level for less than 5 minutes.)
He really needs to learn how to manage expectations better.
Most of of here work or have worked in the business world. That's one of the easiest ways to lose credibility.
Long live the ONCS science!
It's probably better that you leave.
You're deceiving people if you suggest that P2B results will be known this year.
It's clear you didn't listen to conference call today and that you know very little about this company then.
I don't call people names. Only morons do.
Why should I leave? No reason to.
P2B results won't be known until sometime in 2016, correct?
What big pharma will buy ONCS without P2B combination data?
Monotherapies rarely get bought out now. Maybe a year ago, but not now.
Apropos for today.
No. There is only one me.
I sold, and I probably won't be back until the P2B trial has actually enrolled its first patient.
I agree, but the most important data (P2B) won't be released until 2016.
Monotherapy data won't move the needle much anymore. Maybe a year ago, but not now. You have to adjust to changing conditions.
Yes, but it's his fiduciary responsibility not to mislead investors by making invalid/improper statements in person or by tweeting them. One thing you learn to NEVER do is to set false expectations. Especially someone in his position.
His uncle needs to give him a tongue lashing.
I sold because Punit potentially lied to some investors. I want to understand what others think of him as a CEO.
By the way, I love the science, if we can ever get the P2B trial started.
It's possible, Wait, but to me it just doesn't make for a compelling investment case at this point.
We've had data releases in the past. Why are we sitting at 0.35 now? Because those data releases were not SIGNIFICANT to the PPS in a SUSTAINABLE way. And P1 monotherapy trial data will not get it done anymore, IMHO. Only combinatorial trial data will.
Successful P2B data is the only SIGNIFICANT data which can move the PPS higher in a SUSTAINABLE way.